Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Free Cash Flow · Q4 FY2025 · quarter ended Dec 2025
Free cash flow of CN¥25.81M in Q4 FY2025
Q4 FY2025 free cash flow was CN¥25.81M.
Context
- Free cash flow amounted to 0.6% of revenue in FY2025, down 6.5 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
CNY · from the cash flow
- Latest · FY2025
- 703K CNY
- Year-over-year change
- -94.7%
- 4-year CAGR
- -40.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 703K | -94.7% |
| FY2024 | 2024-12-31 | 13.27M | -63.7% |
| FY2023 | 2023-12-31 | 36.58M | +466.1% |
| FY2022 | 2022-12-31 | (9.99M) | -284.7% |
| FY2021 | 2021-12-31 | 5.41M | — |
Free Cash Flow vs competitors
How ZYBT compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -94.7% is the lowest of 9, against a peer median of -1.2%.
- Free cash flow amounts to 0.6% of revenue for ZYBT, versus a peer median of 232.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.76M USD | -25.8% | -48.3% | — | |
| LTM Mar 2026 | $33.68M USD | +85.0% | -12.2% | 449.4% | |
| LTM Mar 2026 | CA$30.89M CAD | +18.0% | +5.6% | — | |
| LTM Mar 2026 | $27.58M USD | +1.6% | -9.4% | 48377.2% | |
| LTM Mar 2026 | CA$24.3M CAD | -4.0% | -4.4% | — | |
| LTM Mar 2026 | $8.99M USD | -31.6% | -24.6% | 16.1% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $7.09M USD | -30.5% | +66.6% | — |
| LTM Mar 2026 | $6.97M USD | +498.5% | +5.2% | 9.3% | |
| FY2025 | CN¥703K CNY | -94.7% | — | 0.6% | |
| Peer median (excluding ZYBT) | — | -1.2% | -6.9% | 232.8% | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 46.47M | 55.74M | 37.51M | 13.47M | (82.97M) |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| Deferred Income Tax | (358K) | (1.09M) | 758K | 924K | 11.1M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (33.71M) | (66.82M) | (20.49M) | (977K) | 44.83M |
| Accounts Receivables | (40.91M) | (47.38M) | 38.05M | 11.31M | 61.41M |
| Inventory | (12.34M) | (12.33M) | (12.9M) | (5.88M) | 6.25M |
| Accounts Payables | 17.63M | (9.67M) | (35.61M) | (404K) | (3.36M) |
| Other Working Capital | 1.91M | 2.56M | (10.03M) | (6M) | (19.47M) |
| Other Non-Cash Items | 3.4M | 10.7M | 6.5M | 3.47M | 14.42M |
| Operating Cash Flow | 31.81M | 17.34M | 48.18M | 41.05M | 13.33M |
| Capital Expenditures | (26.4M) | (27.33M) | (11.6M) | (27.77M) | (12.63M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.22M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.21M) | 0 | (3.15M) | (14.08M) | (11.62M) |
| Investing Cash Flow | (26.27M) | (27.33M) | (11.77M) | (27.67M) | (12.63M) |
| Debt Repayment | 8M | 34.88M | 24.97M | (2.74M) | (12.09M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 43.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.05M) | (21.43M) | (39.45M) | (16.02M) | 0 |
| Other Financing Activities | 0 | (1) | (4.5M) | (3.37M) | 1.32M |
| Financing Cash Flow | (3.05M) | 13.46M | (18.98M) | (22.13M) | 32.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 168K | (1.29M) |
| Net Change in Cash | 2.49M | 3.46M | 17.44M | (8.58M) | 31.73M |
| Free Cash Flow | 5.41M | (9.99M) | 36.58M | 13.27M | 703K |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.